Skip to Content

Pemazyre Side Effects

Generic name: pemigatinib

Medically reviewed by Last updated on May 4, 2020.

Note: This document contains side effect information about pemigatinib. Some of the dosage forms listed on this page may not apply to the brand name Pemazyre.

For the Consumer

Applies to pemigatinib: oral tablet


Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • eye problems--eye pain or redness, dry or puffy eyes, watery eyes, your eyes may be more sensitive to light;

  • vision changes--blurred vision, seeing black spots or "floaters," or seeing flashes of light; or

  • high phosphate levels in your blood--muscle cramps, numbness, tingly feeling around your mouth.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For Healthcare Professionals

Applies to pemigatinib: oral tablet


Very common (10% or more): Hemoglobin decreased (43%), lymphocytes decreased (36%), platelets decreased (28%), leukocytes increased (27%)[Ref]


Very common (10% or more): Arthralgia (25%), back pain (20%), pain in extremity (19%)

Common (1% to 10%): Fractures, pathologic fractures (which include patients with and without cholangiocarcinoma)[Ref]


Very common (10% or more): Dry eye (e.g., dry eye, keratitis, lacrimation increased, pinguecula, punctate keratitis) (25%)

Common (1% to 10%): retinal pigment epithelial detachment (RPED)[Ref]


Very common (10% or more): Hyperphosphatemia (94%), hypophosphatemia (68%), alanine aminotransferase increased (43%), aspartate aminotransferase increased (43%), calcium increased (43%), alkaline phosphatase increased (41%), creatinine increased (41%), sodium increased (39%), glucose increased (36%), albumin decreased (34%), anorexia (33%), urate increased (30%), bilirubin increased (26%), potassium decreased (26%), hypophosphatemia (23%), calcium decreased (17%), weight loss (16%), dehydration (15%), potassium increased (12%), glucose decreased (11%)[Ref]


Very common (10% or more): Urinary tract infection (16%)[Ref]


Very common (10% or more): Fatigue (42%), edema peripheral (18%), dysgeusia (40%), headache (16%)[Ref]


Serious adverse reactions in2% or greater of patients who received this drug included abdominal pain, pyrexia, cholangitis, pleural effusion, acute kidney injury, cholangitis infective, failure to thrive, hypercalcemia, hyponatremia, small intestinal obstruction, and urinary tract infection. Fatal adverse reactions occurred in 4.1% of patients, including failure to thrive, bile duct obstruction, cholangitis, sepsis, and pleural effusion[Ref]


Very common (10% or more): Alopecia (49%), nail toxicity (e.g., nail disorder, nail discoloration, nail dystrophy, nail hypertrophy, nail ridging, nail infection,

onychalgia, onychoclasis, onycholysis, onychomadesis, onychomycosis, paronychia) (43%), dry skin (20%), palmar-plantar erythrodysesthesia syndrome (15%)[Ref]


Very common (10% or more): Diarrhea (47%), nausea (40%), constipation (35%), stomatitis (35%), dry mouth (34%), vomiting (27%), abdominal pain (23%)[Ref]


1. "Product Information. Pemazyre (pemigatinib)." Incyte Corporation, Wilmington, DE.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.